Literature DB >> 9126863

Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock.

L M Chen1, L Chao, J Chao.   

Abstract

Rat kallikrein-binding protein (RKBP) is a negative acute phase protein. The potential role of RKBP in inflammation was evaluated in transgenic mice overexpressing the RKBP gene under the control of the mouse metallothionein metal-responsive promoter. Bacterial endotoxic lipopolysaccharide (LPS) was injected intraperitoneally into mice at a dose of 600 microg/25 g body weight. The death toll was recorded every 12 hours for 3 days. The survival rate of transgenic male mice (n=78) was 33.3% while that of control male mice (n=54) was 9.3% 3 days post LPS injection. In comparison, the survival rate of transgenic female mice (n=59) was 55.9% while that of control female mice (n=65) was 30.8%. Recombinant RKBP levels in the circulation of these mice increased by 3-fold after LPS treatment. The results show that RKBP transgenic mice have a higher survival rate than their non-transgenic control littermates after endotoxin shock and female mice are more resistant to lethality induced by endotoxin shock than male mice in both transgenic and control groups. These findings suggest that kallikrein-binding protein has a protective effect during acute phase inflammation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9126863     DOI: 10.1016/s0024-3205(97)00094-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  18 in total

1.  Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling.

Authors:  Bo Shen; Lin Gao; Yi-Te Hsu; Grant Bledsoe; Makato Hagiwara; Lee Chao; Julie Chao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-08-20       Impact factor: 4.733

Review 2.  Protective Role of Kallistatin in Vascular and Organ Injury.

Authors:  Julie Chao; Grant Bledsoe; Lee Chao
Journal:  Hypertension       Date:  2016-07-18       Impact factor: 10.190

Review 3.  Kallistatin suppresses cancer development by multi-factorial actions.

Authors:  Julie Chao; Pengfei Li; Lee Chao
Journal:  Crit Rev Oncol Hematol       Date:  2017-03-14       Impact factor: 6.312

4.  Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling.

Authors:  Yuying Liu; Grant Bledsoe; Makato Hagiwara; Bo Shen; Lee Chao; Julie Chao
Journal:  Am J Physiol Renal Physiol       Date:  2012-07-18

5.  Kallistatin modulates immune cells and confers anti-inflammatory response to protect mice from group A streptococcal infection.

Authors:  Shiou-Ling Lu; Chiau-Yuang Tsai; Yueh-Hsia Luo; Chih-Feng Kuo; Wei-Chieh Lin; Yu-Tzu Chang; Jiunn-Jong Wu; Woei-Jer Chuang; Ching-Chuan Liu; Lee Chao; Julie Chao; Yee-Shin Lin
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

6.  Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation.

Authors:  Hang Yin; Lin Gao; Bo Shen; Lee Chao; Julie Chao
Journal:  Hypertension       Date:  2010-06-21       Impact factor: 10.190

7.  Fetuin (alpha2-HS-glycoprotein) opsonizes cationic macrophagedeactivating molecules.

Authors:  H Wang; M Zhang; M Bianchi; B Sherry; A Sama; K J Tracey
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

8.  Pivotal role of JNK-dependent FOXO1 activation in downregulation of kallistatin expression by oxidative stress.

Authors:  Bo Shen; Lee Chao; Julie Chao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-01-15       Impact factor: 4.733

9.  Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis.

Authors:  Pengfei Li; Grant Bledsoe; Zhi-Rong Yang; Hongkuan Fan; Lee Chao; Julie Chao
Journal:  Immunology       Date:  2014-06       Impact factor: 7.397

10.  Increased serum kallistatin levels in type 1 diabetes patients with vascular complications.

Authors:  Alicia J Jenkins; Jeffrey D McBride; Andrzej S Januszewski; Connie S Karschimkus; Bin Zhang; David N O'Neal; Craig L Nelson; Jasmine S Chung; C Alex Harper; Timothy J Lyons; Jian-Xing Ma
Journal:  J Angiogenes Res       Date:  2010-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.